Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Lung cancer is the leading cause of cancer-related deaths in North America and other
developed countries. One of the reasons lung cancer is at the top of the list is that it is often …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Introduction Dabrafenib plus trametinib was found to have robust antitumor activity in
patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Introduction Access to targeted therapies for lung cancer depends on the accurate
identification of patients' biomarkers through molecular testing. The International Association …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

In the United States, lung cancer is the second most frequently diagnosed type of cancer
and the leading cause of cancer deaths. 1 Non–small-cell lung cancer (NSCLC), which …

Lung cancer is a malignancy with high morbidity and mortality worldwide. More evidences
indicated that gut microbiome plays an important role in the carcinogenesis and progression …